aap reports Nine-Month Sales of EUR 24.2 million (+30%) and EBIT of EUR 1.3 million (+16%)

aap Implantate AG, a medical technology company listed on the Frankfurt Stock Exchange in the Prime Standard segment and active in medical biomaterials, fracture healing and joint replacement, achieved a 30% growth in sales in the first nine months of the financial year 2008 to EUR 24.2 million (previous year: EUR 18.6 million). This is based primarily on the disproportionately positive business development of the Traumatology & Orthopaedics (aap T&O) division, where sales growth in the past three quarters has been around 57% higher than last year. The Group operating result rose from EUR 1.1 million to EUR 1.3 million.

In EUR million Q1-Q3 2008 Q1-Q3 2007 Change on Year
Sales 24.2 18.6 + 30%

EBITDA 3.7 2.7 + 35%

EBIT 1.3 1.1 + 16%

EBT 0.6 0.8 - 22%

Net period result 0.4 0.2 + 45%

Equity (ratio) 46.8 (63%) 42.6 (67%) + 8%

Balance sheet total 74.0 63.7 + 16%

Employees 302 274 + 10%

In the first three quarters of 2008 the Group earned an EBITDA of EUR 3.7 million (previous year: EUR 2.7 million). Group EBIT was EUR 1.3 million (previous year: EUR 1.1 million) and EBT EUR 0.6 million (previous year: EUR 0.8 million). With total assets of EUR 74.0 million (previous year: EUR 63.7 million) the equity ratio after entry of the capital increase in the Commercial Register was 63%.

Highlights of the third Quarter 2008 were the successfully placed 5% capital increase and the signing of an agreement with Zimmer Holdings Inc. on the distribution of the EASYMIX® vacuum mixing system.

For 2008 aap anticipates furthermore an organic sales growth of more than 20%.

The full report on aap Implantate AG's third quarter of 2008 is available for download at www.aap.de.